Humans

Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis
OBJECTIVES: Calprotectin is an inflammatory marker of interest in rheumatoid arthritis (RA). We evaluated whether the level of …
Maria Karolina Jonsson, Nina Paulshus Sundlisæter, Hilde Haugedal Nordal, Hilde Berner Hammer, Anna-Birgitte Aga, Inge Christoffer Olsen, Karl Albert Brokstad, Désirée van der Heijde, Tore K. Kvien, Bjørg Tilde Svanes Fevang, Siri Lillegraven, Espen A. Haavardsholm
Cite DOI
Efficacy of infliximab biosimilars in patients with Crohn's disease - Authors' reply
Kristin K. Jørgensen, Knut E. Lundin, Inge C. Olsen, Tore K. Kvien, Jørgen Jahnsen
Cite DOI
Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register
OBJECTIVES: Tumour necrosis factor-α inhibitor (TNFi) treatment has been shown to reduce the rates of anterior uveitis (AU) in patients …
Elisabeth Lie, Ulf Lindström, Tatiana Zverkova-Sandström, Inge C. Olsen, Helena Forsblad-d'Elia, Johan Askling, Meliha C. Kapetanovic, Lars Erik Kristensen, Lennart T. H. Jacobsson
Cite DOI
Cardiovascular disease risk profiles in inflammatory joint disease entities
BACKGROUND: Patients with inflammatory joint diseases (IJD) have increased risk of cardiovascular disease (CVD). Our aim was to compare …
Grunde Wibetoe, Eirik Ikdahl, Silvia Rollefstad, Inge C. Olsen, Kjetil Bergsmark, Tore K. Kvien, Anne Salberg, Dag Magnar Soldal, Gunnstein Bakland, Åse Lexberg, Bjørg-Tilde Fevang, Hans Christian Gulseth, Glenn Haugeberg, Anne Grete Semb
Cite DOI
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
BACKGROUND: TNF inhibitors have improved treatment of Crohn’s disease, ulcerative colitis, spondyloarthritis, rheumatoid …
Kristin K. Jørgensen, Inge C. Olsen, Guro L. Goll, Merete Lorentzen, Nils Bolstad, Espen A. Haavardsholm, Knut E. A. Lundin, Cato Mørk, Jørgen Jahnsen, Tore K. Kvien, NOR-SWITCH study group
Cite DOI
Sleep disturbance in patients with rheumatoid arthritis is related to fatigue, disease activity, and other patient-reported outcomes
OBJECTIVES: To explore factors related to sleep disturbance in patients with rheumatoid arthritis (RA). METHOD: Cross-sectional data …
C. Austad, T. K. Kvien, I. C. Olsen, T. Uhlig
Cite DOI
Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register
OBJECTIVE: To investigate whether osteoporosis or use of calcium supplementations predict all-cause mortality, or death from CVD, in a …
Sella A. Provan, Inge C. Olsen, Cathrine Austad, Glenn Haugeberg, Tore K. Kvien, Till Uhlig
Cite DOI
Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria
OBJECTIVES: To compare the presentation of seropositive and seronegative early rheumatoid arthritis (RA) in disease-modifying …
Lena Bugge Nordberg, Siri Lillegraven, Elisabeth Lie, Anna-Birgitte Aga, Inge Christoffer Olsen, Hilde Berner Hammer, Till Uhlig, Maria Karolina Jonsson, Désirée van der Heijde, Tore K. Kvien, Espen Andre Haavardsholm, and the ARCTIC working group
Cite DOI
4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State
Systemic inflammation has been linked to suppressed CYP3A(4) activity. We determined 4β-hydroxycholesterol (4βOHC), an endogenous …
B. M. Wollmann, S. W. Syversen, E. Lie, C. Gjestad, L. L. Mehus, I. C. Olsen, E. Molden
Cite DOI
Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases
OBJECTIVES: Cardiovascular disease (CVD) risk calculators developed for the general population have been shown to inaccurately predict …
A. G. Semb, E. Ikdahl, J. Hisdal, I. C. Olsen, S. Rollefstad
Cite DOI